Gene transfer of anti-gp41 antibody and CD4 immunoadhesin strongly reduces the HIV-1 load in humanized severe combined immunodeficient mice

AIDS

Volumn 14, Issue 18, 2000, Pages 2813-2822

  Sanhadji, Kamel ^a,b   Grave, Linda ^c   Touraine, Jean Louis ^a,b   Leissner, Philippe ^c   Rouzioux, Christine ^d   Firouzi, Réza ^a   Kehrli, Laurence ^a   Tardy, Jean Claude ^a   Mehtali, Majid ^c  

^a UNIVERSITÉ LYON 1   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c TRANSGENE S A   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Anti HIV 1 gp41; Gene therapy; Immunoadhesin; Neo organ; SCID mice

Indexed keywords

CD4 IMMUNOGLOBULIN; GLYCOPROTEIN GP 41; GLYCOPROTEIN GP 41 ANTIBODY; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2F5; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; GENE TRANSFER; HUMAN IMMUNODEFICIENCY VIRUS 1; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; VIRUS LOAD;

3T3 CELLS; ANIMALS; ANTIBODIES, MONOCLONAL; CD4 IMMUNOADHESINS; DISEASE MODELS, ANIMAL; DNA, VIRAL; GENE THERAPY; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MICE; MICE, SCID; TRANSDUCTION, GENETIC; VIRAL LOAD;

EID: 0034518447     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200012220-00002     Document Type: Article

References (48)

1. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
2. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons
3. Human immuno-deficiency virus type 1 mRNA expression in peripheral blood cells predicts disease progression independently of the numbers of CD4+ lymphocytes
4. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease
5. High levels of HIV-in plasma during all stages of infection determined by competitive PCR
6. The SCID-hu mice: Murine model for the analysis of the human hematolymphoid differentiation and function
7. Long-term chimera produced by transplantation of human fetal liver cells into severe combined immunodeficiency (SCID) mouse
8. Infection of the SCID-hu mice by HIV-1
9. Experimental gene therapy: The transfer of Tat-inducible interferon genes protects human cells against HIV-1 challenge in vitro and in vivo in severe combined immunodeficient mice
10. Polymerase chain reaction evidence for human immunodeficiency virus 1 neutralization by passive immunization in patients with AIDS and AIDS-related complex
11. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody
12. Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys
13. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
14. Studies in subject with long-term nonprogressive human immunodeficiency virus infection
15. Antibody neutraliztlion-resistant primary isolates of human immunodeficiency virus type 1
16. Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins
17. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12
18. Effects of soluble CD4 on simian immunodeficiency virus infection of CD4-positive and CD4-negative cells
19. Quantitative model of antibody and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1
20. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage
21. Phase 1 study of highdose, intravenous rsCD4 in subjects with advanced HIV1 infection
22. Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: A phase I study
23. Further evaluation of soluble CD4 as an anti-HIV type 1 gene therapy: Demonstration of protection of primary human peripheral blood lymphocytes from infection by HIV type 1
24. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1
25. The CD4 molecule and HIV infection
26. Correction of lysosomal storage in the liver and spleen of MPS VII mice by implantation of genetically-modified skin fibroblasts
27. Simple, rapid, quantitative, syncytium-forming microassay for detection of human immunodeficiency virus neutralizing antibody
28. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and EBV-transformation for PBLs immortalization
29. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody
30. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1
31. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS
32. Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins
33. The consequence of passive administration of anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate
34. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site
35. Passive immunization with a human immunodeticiency virus type 1 neutralizing monoclonal antibody in hu-PBL-SCID mice: Isolation of a neutralization escape variant
36. Human monoclonal antibodies against gp41 and gp120 as potential agent for passive immunization
37. Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen
38. A soluble form of CD4 (T4) protein inhibits AIDS virus infection
39. Characterization of in vitro inhibition of human immunodeficiency virus by purified recombinant CD4
40. Continuous secretion of human soluble CD4 in mice transplanted with genetically modified cells
41. Designing CD4 immunoadhesins for AIDS therapy
42. Expression and characterization of CD4-G2, a novel heterotetramer that neutralizes primary HIV type 1 isolates
43. CD4-pseudomonas exotoxin conjugates delay but do not fully inhibit human immunodeficiency virus replication in lymphocytes in vitro
44. CD4-induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: Consequences for virus entry and neutralization
45. Soluble CD4 induces the binding of human immunodeficiency virus type 1 to cells via the V3 loop of glycoprotein 120 and specific sites in glycoprotein 41
46. Epitope exposure on functional, oligomeric HIV1 gp41 molecules
47. Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV1 neutralization
48. Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cell